RxDoctor Payments Data

Timothy Brown, DO

Hospitalist · Clinton, SCNPI 1902033624

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 27.4% of the total.

$552in general payments, 2019–2025

Across 17 payments — averaging $32.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$151
  • Abbott$102
  • Mallinckrodt Hospital Products Inc.$72
  • Vifor Pharma, Inc.$49
  • Otsuka America Pharmaceutical, Inc.$45
  • GSK$41
  • plus $92 from 4 others

What the payments were for

  • Food & beverage$552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$552 in reported general payments places this provider in the 85th percentile of 398 hospitalist providers in South Carolina.

See all hospitalist providers in South Carolina

Medicare billing

Part B allowed, 2024
$12,305
Medicare patients
54
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate13$1,765
Doxazosin Mesylate14$602
Amlodipine Besylate23$70

Paid to pharmacies, not to this prescriber.

Other hospitalist in Clinton

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →